Clinical Trials Directory

Trials / Completed

CompletedNCT00641147

Curcumin in Treating Patients With Familial Adenomatous Polyposis

Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
44 (actual)
Sponsor
National Cancer Institute (NCI) · NIH
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

This randomized phase II trial studies curcumin in treating patients with familial adenomatous polyposis. Curcumin may prevent colorectal cancer in patients with a history of rectal polyps or colorectal neoplasia.

Detailed description

Specific Aims: I. To determine in a randomized, double-blinded, placebo-controlled study the tolerability and effectiveness of curcumin to regress intestinal adenomas by measuring duodenal and colorectal/ileal polyp number, and polyp size in familial adenomatous polyposis patients with intact colons, ileorectal anastomosis surgery, or ileo-anal pullthrough (reservoir) surgery. II. To measure markers of cell proliferation including colorectal mucosal levels of ornithine decarboxylase (ODC), polyamines, mucosal deoxyribonucleic acid (DNA) methylation, proliferative index (Ki67 antiproliferative cell nuclear antibody), apoptosis index, vascular density, mucosal prostaglandin, leukotriene levels, and activation of the nuclear factor kappa B (NFKB), and v-akt murine thymoma viral oncogene homolog 1 (Akt) survival pathways. OUTLINE: Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive curcumin orally (PO) twice daily (BID) for 12 months. Arm II: Patients receive placebo PO BID for 12 months. After completion of study treatment, patients are followed up at 4 months.

Conditions

Interventions

TypeNameDescription
DRUGCurcuminGiven PO
OTHERLaboratory Biomarker AnalysisCorrelative studies
OTHERPlaceboGiven PO

Timeline

Start date
2010-10-01
Primary completion
2016-11-01
Completion
2016-11-30
First posted
2008-03-24
Last updated
2017-09-29
Results posted
2017-09-29

Locations

2 sites across 2 countries: United States, Puerto Rico

Source: ClinicalTrials.gov record NCT00641147. Inclusion in this directory is not an endorsement.